Table 2. Overview of TEAEs and most common TEAEs (occurring in ≥ 5% of patients) across studies of perampanel as monotherapy (Safety Analysis Sets)

			Study 342 (FREEDOM)	
	Study 504 (n=60)[a]	**Study 506 (PROVE) (n=47)[a]**	Perampanel 4 mg/day (n=89)	Perampanel 4 and 8 mg/day (n=89)
TEAEs, n (%)	22 (36.7)	17 (36.2)	57 (64.0)	67 (75.3)
Treatment-related TEAEs, n (%)	NR	NR	38 (42.7)	47 (52.8)
Serious TEAEs, n (%)	1 (1.7)	2 (4.3)	9 (10.1)	9 (10.1)
Most common TEAEs reported in ≥ 5% patients in any group, n (%)				
Dizziness	9 (15.0)	6 (12.8)	20 (22.5)	28 (31.5)
Nasopharyngitis	0 (0.0)	0 (0.0)	11 (12.4)	13 (14.6)
Somnolence	4 (6.7)	2 (4.3)	11 (12.4)	12 (13.5)
Headache	3 (5.0)	1 (2.1)	10 (11.2)	10 (11.2)
Epilepsy	0 (0.0)	0 (0.0)	5 (5.6)	5 (5.6)
Irritability	7 (11.7)	0 (0.0)	2 (2.2)	3 (3.4)
Gait disturbance	0 (0.0)	3 (6.4)	1 (1.1)	1 (1.1)

A patient with ≥ 2 TEAEs is counted only once for that event

[a]Includes patients receiving primary or secondary monotherapy

NR, not reported; TEAE, treatment-emergent adverse event